Connor, Clark & Lunn Investment Management (CC&L)
SRRA

Connor, Clark & Lunn Investment Management (CC&L)’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio SRRA Stock Details SRRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-24,685
Closed -$791K – 1257
2022
Q1 		$791K Buy
+24,685
New +$708K ﹤0.01% 703
2019
Q2 		– Sell
-1,026
Closed -$70K – 1101
2019
Q1 		$70K Sell
1,026
-200
-16% -$12.8K ﹤0.01% 883
2018
Q4 		$65K Sell
1,226
-848
-41% -$54.2K ﹤0.01% 916
2018
Q3 		$141K Sell
2,074
-500
-19% -$45.3K ﹤0.01% 868
2018
Q2 		$305K Buy
2,574
+524
+26% +$52.6K ﹤0.01% 880
2018
Q1 		$170K Buy
2,050
+1,432
+232% +$162K ﹤0.01% 665
2017
Q4 		$92K Buy
618
+318
+106% +$30.6K ﹤0.01% 754
2017
Q3 		$19K Sell
300
-15
-5% -$880 ﹤0.01% 798
2017
Q2 		$15K Sell
315
-55
-15% -$2.81K ﹤0.01% 804
2017
Q1 		$23K Buy
+370
New +$21.5K ﹤0.01% 885
2016
Q4 		– Sell
-370
Closed -$27K – 1017
2016
Q3 		$27K Buy
370
+95
+35% +$7.34K ﹤0.01% 819
2016
Q2 		$22K Buy
+275
New +$52.4K ﹤0.01% 852

Other funds holding SRRA

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VI
Versor Investments New York $47.5M AUM 100.43% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s SRRA Position: Q2 2022 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q2 2022, closing a stake of 24,685 shares — an estimated $791K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in SRRA in Q2 2016 and held it in 12 quarters. The position peaked at $791K in Q1 2022. 109 funds tracked by Wall St. Rank hold SRRA as of Q2 2022.

  • Connor, Clark & Lunn Investment Management (CC&L) reported no remaining Sierra Oncology, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 24,685 Sierra Oncology, Inc. Common Stock shares in Q2 2022, an estimated $791K.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2016 and held it in 12 quarters.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Sierra Oncology, Inc. Common Stock position peaked at $791K in Q1 2022.
  • 109 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q2 2022.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2022, filed 5 Aug 2022.